Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q1 2020 · 10-Q
Revenue$17.12K$17.12K−58.6% vs Q1 2019 Net Income$2.18M$2.18MN/M vs Q1 2019 EPS Diluted$0.00$0.00— vs Q1 2019 Gross Profit$11,837−53.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Operating Cash Flow-$215,555N/M Margins · derivedGross margin69.2%+7.0 pt vs Q1 2019
Operating margin-1110.7%−508.2 pt vs Q1 2019
Net margin12754.4%+13723.5 pt vs Q1 2019
ended Mar 31, 2020 · filed Jul 23, 2021 · 479 d after period end